Harbour BioMed

Alzheon, Inc. is a clinical-stage biopharmaceutical company based in Framingham, MA, dedicated to developing innovative treatments for Alzheimer's disease and other neurodegenerative disorders. Founded in 2013 by Dr. Martin Tolar, the company is advancing its investigational oral anti-amyloid therapy, valiltramiprosate, through late-stage clinical trials, focusing initially on high-risk patients with the APOE4 gene variant. With a strong emphasis on precision medicine, Alzheon utilizes its expertise in inhibiting protein misfolding and aggregation to create disease modifying therapies. The company has successfully completed Phase 2 and Phase 3 trials, receiving substantial funding from the National Institute on Aging to support its research efforts. Generated from the website

Xenetic Biosciences Inc., based in Framingham, MA, is a biopharmaceutical company dedicated to advancing proprietary technology platforms aimed at tackling high-value cancer indications. The company is focused on developing innovative immune-oncology technologies, particularly targeting Neutrophil Extracellular Traps (NETs), which play a significant role in cancer progression and treatment resistance. Leveraging its DNase I Oncology Platform, Xenetic is committed to improving cancer therapies, with a current emphasis on challenging conditions such as pancreatic cancer and other solid tumors. The company maintains an active pipeline and regularly updates stakeholders on its clinical advancements and financial results. Generated from the website

Anagram Therapeutics is a biopharmaceutical company based in Framingham, MA, dedicated to developing breakthrough orally-delivered enzyme therapeutics for rare, life-threatening diseases. Their focus lies in treating malabsorption syndromes and nutrient metabolism disorders caused by enzyme deficiencies or genetic mutations, aiming to provide effective solutions for individuals who are currently inadequately treated or have no treatment options at all. With a team of world-class researchers and collaborators, Anagram Therapeutics is powered by innovative technology and expertise in enzymes and gastrointestinal physiology. They are committed to realigning and reimagining orally-delivered enzymes to make a meaningful difference in the lives of infants, children, and adults affected by these debilitating conditions, as well as their families.Generated from the website